SCC-Ag、CA19-9、CEA在肺癌患者血清中的变化及临床意义

Clinical Significance of Changes of Serum SCC-Ag,CA19-9 and CEA Levels in Patients with Lung Cancer

目的:探讨肺癌患者血清鳞状上皮细胞癌抗原(squamous cell carcinoma antigen,SCC-Ag)、糖类抗原CA19-9、癌胚抗原(CEA)的变化及临床意义。方法:采用微粒子酶免分析测定98例肺癌、50例良性肺病患者血清SCC-Ag水平,并用化学发光法测定其CA19-9和CEA水平,分析SCC-Ag、CA19-9和CEA检测值与肺癌临床病理特征之间的关系。结果:肺癌患者组SCC-Ag、CA19-9和CEA水平明显高于健康对照组和良性肺病组(P<0.01),肺癌患者组SCC-Ag、CA19-9和CEA升高与肿瘤病理学类型相关和临床分期呈正相关(P<0.01),SCC-Ag检测阳性率以鳞癌最高,CA19-9和CEA检测阳性率以腺癌最高。结论:该三项肿瘤标志物可用于肺癌的辅助诊断以及对病期和预后的判断。

Objective To investigate the clinical significance of changes of serum squamous cell carcinoma antigen （ SCC - Ag） and cancer antigen19 -9 （CA19 -9） and careinoembryanic antigen （CEA） levels in patients with lung cancer. Methods The serum levels of SCC - Ag （with MEIA）, CA19 -9 and CEA （with CLIA） levels determined in 98 patients with lung cancer, 50 patients with benign lung diseases and （35 on 25 controls）. Results The serum levels of SCC - Ag, CA19 -9 and CEA in the patients with lung cancer were significantly higher than those in patients with benign lung disease and controls （P 〈 0.01 ）. Among the cancer patients, the serum SCC - Ag levels in patients with squamous cell carcinoma were significantly higher than those in patients with adenocarcinoma, the reverse was true for serum CA19 -9 and CEA levels. As the disease progressed from stage Ⅰ to stage Ⅳ, the levels of these markers also progreesively increased. Conclusion The combined determinotion of three tumor markers could be helpful for the diagnosis, prediction of prognosis and monitoing recurrence in patients with lung cancer.